Table 1 Tumor cellularity in biopsies and surgical specimens

From: The identification of challenges in tissue collection for biomarker studies: the Q-CROC-03 neoadjuvant breast cancer translational trial experience

Collection

Not evaluable

no tumor cells

<50% tumor

≥50% tumor

Total evaluated

Pre-chemo therapy biopsies

4.6% (n=8)

14.5% (n=25)

43.7% (n=75)

37.2% (n=64)

172

Post-chemo therapy biopsies

5% (n=3)

30% (n=18)

31.7% (n=19)

33.3% (n=20)

60

Surgical specimens

0

29.6% (n=19)

15.6% (n=10)

54.7% (n=35)

64